Currently Viewing:
Newsroom
Currently Reading
Headache Disorders Play Significant Role in Disability Globally and Require More Attention, Study Finds
December 12, 2018 – Alison Rodriguez
Pennsylvania Auditor General Calls for Action on PBMs
December 12, 2018 – Allison Inserro
Diet Has Minimal Association With Breast Cancer Risk in Postmenopausal Women, Study Finds
December 12, 2018 – David Bai, PharmD
Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation
December 12, 2018 – Jaime Rosenberg
What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption
December 12, 2018 – AJMC Staff
What We're Reading: High Court Lets Abortion Cases Stand; NIH and Fetal Tissue; Dsuvia Examined
December 11, 2018 – AJMC Staff
Durvalumab Combination Fails to Meet Primary End Point in NSCLC Trial
December 11, 2018 – Samantha DiGrande
Rate of Uninsured Increased in 2017 for the First Time Since 2014
December 11, 2018 – Allison Inserro
More Than 300 Groups Seek Halt to CMS' Plans for Global Drug Pricing Index
December 10, 2018 – Allison Inserro

Switchable CAR T Cells May Be Safer in Pancreatic Cancer

David Bai, PharmD
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.

PDAC is the fourth leading cause of cancer-related deaths, with less than 20% of patients having resectable tumors. While CAR T-cell treatments have shown substantial efficacy in hematological malignancies, outcomes in solid tumors such as pancreatic cancer have been limited. Further, since the antigen is expressed on tumors as well as normal tissue, CAR T-cell toxicities can affect healthy organs as well. Attempts are currently being made to create “switchable” CAR T cells whose activity can be titrated in vivo so that they are more specific toward tumors. Allowing CAR T cells to bind a peptide specifically onto a tumor-binding Fab molecule creates a bridge that can connect the target tumor and effector T-cells, thereby regulating treatment and enhancing safety. 

In their study published in Gut, Raj et al used CAR T cells drawn from patients with stage IV PDAC to determine if switchable CAR T cells have comparable efficacy as conventional CAR-T cells while targeting HER2, a viable target in PDAC. When comparing conventional CAR-T cells with switchable CAR-T cells, both were able to induce cytotoxicity in HER2-expressing PDAC cells. In addition, when an inactive switch of a wild-type HER2 Fab was placed, there was no cytotoxic effect on PDAC cells, identifying the importance of the switch. 

To further examine the effectiveness of CAR T cells in PDAC, investigators created a microenvironment of cancer stem cells—a physical barrier for T cell connection with tumor cells in vitro. Following a few days of culture, CAR T-cell activity was observed in both treatment groups, marked by increased T cell proliferation and enhanced production of the cytotoxic molecule granzyme B. 

Subsequent studies evaluated the efficacy of HER2 CAR T and switchable CAR T cells in vivo. Immunocompromised mice were implanted with patient PDAC cells and treated with both types of CAR T-cell therapy. Non-invasive bioluminescence imaging of the mice showed reduced tumor growth by day 3 and tumors disappeared by day 10 as. However, mice that had received no treatment or CAR T-cell treatment with an inactive switch continued to progress. 

The efficacy of switchable CAR T and conventional CAR T therapy were also compared through dose titrations. Similar tumor regression was observed in both treatment groups, with similar interferon and tumor necrosis factor cytokine release at each T cell dose, with the exception that IL-2 was higher in the conventional CAR-T cell group. 

Finally, when comparing conventional CAR T with switchable CAR T-cell therapy in disseminated metastasis, rapid tumor clearance was observed in both treatment groups. The mice treated with either therapies remained tumor free for the remainder of the study, which was 5 months following T cell administration. From these mouse models, it seems that switchable CAR T therapy can be effectively used to treat PDAC even in the more advanced cases, while also having a better safety profile than conventional CAR-T therapy.

Reference

Raj D, Yang M, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma [published online August 18, 2018]. Gut.doi: 10.1136/gutjnl-2018-316595.

Related Articles

Rucaparib May Have Potential Clinical Benefit for Advanced Pancreatic Cancer
Single Resistant Cell Causes Case of Rare ALL Relapse After CAR T Therapy
Researcher Looks Ahead to Future Improvements in CAR T
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!